Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4501 - 4525 of 8235 in total
Sibeprenlimab is under investigation in clinical trial NCT05248659 (Phase 2/3 Open-label Trial of Sibeprenlimab in the Treatment of Immunoglobulin a Nephropathy).
Investigational
Matched Description: … in the Treatment of Immunoglobulin a Nephropathy). ... Sibeprenlimab is under investigation in clinical trial NCT05248659 (Phase 2/3 Open-label Trial of Sibeprenlimab …
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic ... dose of bezafibrate, an anti-cholesterol agent. ... In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have …
Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows...
Investigational
Matched Description: … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward ... Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections ... SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of
Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative...
Investigational
Matched Description: … Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative ... The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm ... wound healing and is a potent inducer of physiologic angiogenesis. …
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease. GFT14 is destined to improve the condition of patients at risk from cardiovascular disease...
Investigational
Matched Description: … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of ... GFT14 is a new class of medicaction for treatment of cardiometabolic disease. ... and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides) …
Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct...
Investigational
Matched Description: … the sporadic form of Parkinson's disease. ... link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease. ... In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular …
Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of...
Investigational
Matched Description: … type 2 diabetes are resistant to the effects of insulin. ... These people are said to be resistant to the effects of leptin, in much the same way that people with ... signal that reduces appetite, in general, obese people have an unusually high circulating concentration of
Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. The 3 main targeted species are the deep sea shark (Centrophorus squamosus), the dogfish (Sqaulus acanthias), and the basking shark (Cetorhinus maximus). Shark oil is a rich source of...
Experimental
Matched Description: … Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body ... Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated ... However the major component is considered to be squalene, which may range up to 90% of the shark oil, …
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
Matched Description: … used to treat a variety of solid tumors. ... AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product …
Wortmannin is a steroid metabolite of Penicillium funiculosum and Talaromyces wortmannii fungi. This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).
Experimental
Matched Description: … Wortmannin is a steroid metabolite of _Penicillium funiculosum_ and _Talaromyces wortmannii_ fungi. ... This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks). …
Enarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease).
Investigational
Matched Description: … on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease). ... Enarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib …
PL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).
Investigational
Matched Description: … Drug for the Treatment of Patients With Mild to Moderate Asthma). ... PL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study …
Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).
Investigational
Matched Description: … Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of
Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).
Investigational
Matched Description: … VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty). ... Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.[A259073, A259078]
Investigational
Matched Description: … for the treatment of immune disorders, such as immune thrombocytopenic purpura. ... Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated …
Imdusiran is under investigation in clinical trial NCT06245291 (Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection).
Investigational
Matched Description: … With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection). ... Imdusiran is under investigation in clinical trial NCT06245291 (Study of Imdusiran (AB-729) in Combination …
Benzoylecgonine is the major metabolite of cocaine. It is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. It is excreted in the urine of cocaine users after processing in the liver. It is the main pharmaceutical ingredient in the investigational drug Esterom, a topical solution used for...
Experimental
Illicit
Matched Description: … Benzoylecgonine is the major metabolite of cocaine. ... It is excreted in the urine of cocaine users after processing in the liver. ... It is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. …
rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide...
Investigational
Matched Description: … in individuals with low levels of Mannose-Binding Lectin (MBL). ... Over 10 percent of the general population is estimated to be MBL-deficient. ... Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains. …
Strepronin is a mucolytic drug. A mucolytic agent is any agent which dissolves thick mucus usually used to help relieve respiratory difficulties. The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as well as the presence of disulfide bonds between these macromolecules and DNA.
Experimental
Matched Description: … The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as ... well as the presence of disulfide bonds between these macromolecules and DNA. …
An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids. It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which is the rate limiting enzyme in the biosynthesis of cholesterol.
Experimental
Matched Description: … limiting enzyme in the biosynthesis of cholesterol. ... coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which is the rate ... It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl …
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Investigational
Matched Description: … Food on the Pharmacokinetics of the 2 New Concept Formulations). ... is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of ... Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
Matched Description: … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. ... It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. …
Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM).
Investigational
Matched Description: … Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). ... Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of
Piritrexim has been used in trials studying the treatment of Bladder Cancer, Urethral Cancer, and Transitional Cell Cancer of the Renal Pelvis and Ureter.
Investigational
Matched Description: … Cell Cancer of the Renal Pelvis and Ureter. ... Piritrexim has been used in trials studying the treatment of Bladder Cancer, Urethral Cancer, and Transitional …
Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
Investigational
Matched Description: … and metabolic status of Candida albicans cells within biofilms. ... Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology …
Displaying drugs 4501 - 4525 of 8235 in total